NAGOYA UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1871-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.nagoya-u.ac.jp/en
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Urothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma Urethra
- Interventions
- Drug: Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 43
- Registration Number
- NCT06983210
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya-shi, Aichi, Japan
Deep Learning-based Artificial Intelligence for the Diagnosis of Small Bowel Obstruction
Active, not recruiting
- Conditions
- Bowel ObstructionArtificial Intelligence
- Interventions
- Diagnostic Test: Artificial intelligence
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 17
- Registration Number
- NCT06481358
- Locations
- 🇯🇵
Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Investigator-initiated Clinical Trial of MIKE-1
Phase 1
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 55
- Registration Number
- NCT05064618
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
🇯🇵The University of Tokyo Hospital, Tokyo, Japan
The Clinical Trial of ADR-001 for IgA Nephropathy
Phase 1
Completed
- Conditions
- Glomerulonephritis , IGA
- Interventions
- Biological: infusion of ADR-001 (Mesenchymal stem cell)
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 9
- Registration Number
- NCT04342325
- Locations
- 🇯🇵
Kasugai Municipal Hospital, Kasugai, Aichi, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy
Phase 1
Completed
- Conditions
- Hypoxia-Ischemia, Brain
- Interventions
- Biological: CL2020 cells
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 9
- Registration Number
- NCT04261335
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
Phase 2
Completed
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- Biological: Rituximab (genetical recombination)Other: Placebo
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 25
- Registration Number
- NCT03864185
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
🇯🇵Chiba University Hospital, Chiba, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice
Not Applicable
Terminated
- Conditions
- Neonatal Jaundice
- Interventions
- Other: Low irradiance level of phototherapyOther: High irradiance level of phototherapy
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 100
- Registration Number
- NCT03055481
- Locations
- 🇯🇵
Anjo Kosei Hospital, Anjo, Aichi, Japan
🇯🇵Handa City Hospital, Handa, Aichi, Japan
🇯🇵Hekinan Municipal Hospital, Hekinan, Aichi, Japan
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Phase 2
- Conditions
- Borderline Resectable Pancreatic Cancer
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 50
- Registration Number
- NCT02717091
Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence
Phase 3
Completed
- Conditions
- Urinary Incontinence , Stress
- Interventions
- Biological: Periurethral injection of autologous ADRCs and adipose tissue
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 45
- Registration Number
- NCT02529865
- Locations
- 🇯🇵
Nagoya university Hospital, Nagoya, Aichi, Japan
🇯🇵Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵Shinshu University Hospital, Matsumoto, Nagano, Japan
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
Phase 4
- Conditions
- Hypertensive Left Ventricular Hypertrophy
- Interventions
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 100
- Registration Number
- NCT01893788
- Locations
- 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan